DDInter1562 DDInter437
Raloxifene is a second generation selective estrogen receptor modulator (SERM) that mediates anti-estrogenic effects on breast and uterine tissues, and estrogenic effects on bone, lipid metabolism, and blood coagulation.[A4979,T28] Exhibiting tissue-specific effects distinct from [estradiol], raloxifene is the first of the benzothiophene group of antiestrogens to be labelled a SERM. Available in many countries worldwide, raloxifene was initially approved by the FDA in December, 1997 under the market name Evista® for the management and prevention of osteoporosis in postmenopausal women and reduction in risk for invasive breast cancer in postmenopausal women with osteoporosis or those who are at high risk for invasive breast cancer. However, it has a negligible effect on altering the development and progression of breast cancer itself.[label] The most common causes of osteoporosis
C1 Esterase Inhibitor (Recombinant) is a recombinant analogue of endogenous complement component-1 esterase inhibitor (rhC1INH), purified from the milk of transgenic rabbits. The primary function of endogenous C1INH is to regulate the activation of the complement and contact system pathways. It does this through inhibition of several target proteases within these pathways including activated C1s, kallikrein, factor XIIa and factor XIa. C1 esterase inhibitor has also been shown to inhibit the action of thrombin within the coagulation pathway, and tPA and plasmin within the fibrinolytic pathway. Deficiency of C1-inhibitor allows for increased plasma kallikrein activation and subsequent production of bradykinin. Additionally, C4 and C2 cleavage occurs resulting in auto-activation of the complement system. Down-stream effects of the lack of enzyme inhibition by C1 esterase inhibitor results in swelling due to leakage of fluid from blood vessels into connective tissue and consequently the presentation of hereditary angioedema (HAE). Marketed as the product Ruconest (FDA), this drug is indicated for the treatment of acute attacks of hereditary angioedema (HAE) due to C1 esterase inhibitor deficiency in adults. Intravenous replacement of C1 esterase inhibitor results in reversal of acute symptoms of HAE.
Raloxifene {u} (Compound) treats {v} (Disease) breast cancer
breast cancer {u} (Disease) is treated by {v} (Compound) Toremifene
Toremifene {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Conestat alfa
Raloxifene {u} (Compound) binds {v} (Gene) ESR1
ESR1 {u} (Gene) is bound by {v} (Compound) Toremifene
Toremifene {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Conestat alfa
Raloxifene {u} (Compound) treats {v} (Disease) breast cancer
breast cancer {u} (Disease) is palliated by {v} (Compound) Testosterone
Testosterone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Conestat alfa
Raloxifene {u} (Compound) upregulates {v} (Gene) CYP1A1
CYP1A1 {u} (Gene) is bound by {v} (Compound) Toremifene
Toremifene {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Conestat alfa
Raloxifene {u} (Compound) upregulates {v} (Gene) SQSTM1
SQSTM1 {u} (Gene) is upregulated by {v} (Compound) Toremifene
Toremifene {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Conestat alfa
Raloxifene {u} (Compound) upregulates {v} (Gene) CYP1A1
CYP1A1 {u} (Gene) is bound by {v} (Compound) Thalidomide
Thalidomide {u} may lead to a major life threatening interaction when taken with {v} Conestat alfa
Raloxifene {u} (Compound) upregulates {v} (Gene) TSC22D3
TSC22D3 {u} (Gene) is upregulated by {v} (Compound) Thalidomide
Thalidomide {u} may lead to a major life threatening interaction when taken with {v} Conestat alfa
Raloxifene {u} (Compound) upregulates {v} (Gene) ECH1
ECH1 {u} (Gene) is downregulated by {v} (Compound) Estradiol
Estradiol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Conestat alfa
Raloxifene {u} (Compound) downregulates {v} (Gene) IER3
IER3 {u} (Gene) is upregulated by {v} (Compound) Toremifene
Toremifene {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Conestat alfa
Raloxifene {u} (Compound) downregulates {v} (Gene) IER3
IER3 {u} (Gene) is downregulated by {v} (Compound) Lenalidomide
Lenalidomide {u} may lead to a major life threatening interaction when taken with {v} Conestat alfa
Raloxifene (Compound) treats breast cancer (Disease) and breast cancer (Disease) is treated by Toremifene (Compound) and Toremifene may cause a moderate interaction that could exacerbate diseases when taken with Conestat alfa
Raloxifene (Compound) binds ESR1 (Gene) and ESR1 (Gene) is bound by Toremifene (Compound) and Toremifene may cause a moderate interaction that could exacerbate diseases when taken with Conestat alfa
Raloxifene (Compound) treats breast cancer (Disease) and breast cancer (Disease) is palliated by Testosterone (Compound) and Testosterone may cause a moderate interaction that could exacerbate diseases when taken with Conestat alfa
Raloxifene (Compound) upregulates CYP1A1 (Gene) and CYP1A1 (Gene) is bound by Toremifene (Compound) and Toremifene may cause a moderate interaction that could exacerbate diseases when taken with Conestat alfa
Raloxifene (Compound) upregulates SQSTM1 (Gene) and SQSTM1 (Gene) is upregulated by Toremifene (Compound) and Toremifene may cause a moderate interaction that could exacerbate diseases when taken with Conestat alfa
Raloxifene (Compound) upregulates CYP1A1 (Gene) and CYP1A1 (Gene) is bound by Thalidomide (Compound) and Thalidomide may lead to a major life threatening interaction when taken with Conestat alfa
Raloxifene (Compound) upregulates TSC22D3 (Gene) and TSC22D3 (Gene) is upregulated by Thalidomide (Compound) and Thalidomide may lead to a major life threatening interaction when taken with Conestat alfa
Raloxifene (Compound) upregulates ECH1 (Gene) and ECH1 (Gene) is downregulated by Estradiol (Compound) and Estradiol may cause a moderate interaction that could exacerbate diseases when taken with Conestat alfa
Raloxifene (Compound) downregulates IER3 (Gene) and IER3 (Gene) is upregulated by Toremifene (Compound) and Toremifene may cause a moderate interaction that could exacerbate diseases when taken with Conestat alfa
Raloxifene (Compound) downregulates IER3 (Gene) and IER3 (Gene) is downregulated by Lenalidomide (Compound) and Lenalidomide may lead to a major life threatening interaction when taken with Conestat alfa